Cell And Gene Therapy: An Expert Perspective On The State Of The Industry

By Tim Hunt, CEO, Alliance For Regenerative Medicine (ARM)

There has been tremendous progress in the cell and gene therapy field as the science advances and the sector continues to mature. Since 2018, five gene therapies have been approved for rare disease indications. 2022 was an important year for the sector, with six new therapies approved—including the first allogeneic T-cell therapy—and five existing therapies approved in new geographies or indications.

Review the current state of the cell and gene therapy industry as Tim Hunt, CEO of the Alliance for Regenerative Medicine (ARM), provides a briefing on the cell and gene therapy development landscape. Learn about upcoming approvals as well as challenges and potential progress with payor systems and expanding accessibility.